WO2011000566A3 - Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections - Google Patents

Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections Download PDF

Info

Publication number
WO2011000566A3
WO2011000566A3 PCT/EP2010/003967 EP2010003967W WO2011000566A3 WO 2011000566 A3 WO2011000566 A3 WO 2011000566A3 EP 2010003967 W EP2010003967 W EP 2010003967W WO 2011000566 A3 WO2011000566 A3 WO 2011000566A3
Authority
WO
WIPO (PCT)
Prior art keywords
negative
pharmaceutical compositions
compounds
treatment
virus infections
Prior art date
Application number
PCT/EP2010/003967
Other languages
French (fr)
Other versions
WO2011000566A2 (en
Inventor
Dirk Classen-Houben
Oliver Szolar
Peter Sehr
Bernd Wendt
Delphine Gulligay
Stephen Cusack
Joe Lewis
Original Assignee
Savira Pharmaceuticals Gmbh
European Molecular Biology Laboratory (Embl)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US22190209P priority Critical
Priority to US61/221,902 priority
Priority to US25111809P priority
Priority to US61/251,118 priority
Application filed by Savira Pharmaceuticals Gmbh, European Molecular Biology Laboratory (Embl) filed Critical Savira Pharmaceuticals Gmbh
Publication of WO2011000566A2 publication Critical patent/WO2011000566A2/en
Publication of WO2011000566A3 publication Critical patent/WO2011000566A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/121Ketones acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Abstract

The present invention relates to novel compounds and pharmaceutical compositions and the use thereof for the manufacture of a medicament for treating, ameliorating, or preventing disease conditions caused by a viral infection with negative-sense ssRNA viruses.
PCT/EP2010/003967 2009-06-30 2010-06-30 Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections WO2011000566A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US22190209P true 2009-06-30 2009-06-30
US61/221,902 2009-06-30
US25111809P true 2009-10-13 2009-10-13
US61/251,118 2009-10-13

Publications (2)

Publication Number Publication Date
WO2011000566A2 WO2011000566A2 (en) 2011-01-06
WO2011000566A3 true WO2011000566A3 (en) 2011-05-26

Family

ID=43234276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/003967 WO2011000566A2 (en) 2009-06-30 2010-06-30 Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections

Country Status (1)

Country Link
WO (1) WO2011000566A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57869B1 (en) 2009-06-17 2018-12-31 Vertex Pharma Inhibitors of influenza viruses replication
EP2625169B1 (en) 2010-10-05 2015-03-25 Purdue Pharma L.P. Quinazoline compounds as sodium channel blockers
BR112013010241B1 (en) * 2010-10-28 2018-03-20 The Procter & Gamble Company Personal care compositions understanding a pirition and an iron cheer
WO2012074473A1 (en) * 2010-11-30 2012-06-07 Ge Healthcare Bio-Sciences Ab Screening method
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
TWI619715B (en) 2011-08-01 2018-04-01 維泰克斯製藥公司 Inhibitors of influenza viruses replication
US20130102601A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20130102600A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
KR20150009553A (en) 2012-05-23 2015-01-26 사피라 파르마슈티칼즈 게엠베하 7-Oxo-Thiazolopyridine Carbonic Acid Derivatives and Their Use in the Treatment, Amelioration or Prevention of a Viral Disease
US20130317021A1 (en) 2012-05-23 2013-11-28 Savira Pharmaceuticals Gmbh Heterocyclic pyrimidine carbonic acid derivatives which are useful in the treatment, amelioration or prevention of a viral disease
US20150164910A1 (en) * 2012-06-15 2015-06-18 The Regents Of The University Of Califonia Antiviral compounds and methods of use
US8921388B2 (en) 2012-08-06 2014-12-30 European Molecular Biology Laboratory Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
EA201591291A1 (en) 2013-01-08 2015-12-30 Савира Фармасьютикалз Гмбх Derivatives of pyrimidon and their application in treatment, facilitation or prevention of viral disease
US9199987B2 (en) 2013-01-08 2015-12-01 Savira Pharmaceuticals Gmbh Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease
CN104903294A (en) 2013-01-08 2015-09-09 萨维拉制药有限公司 Pyridone derivatives and their use in treatment, amelioration or prevention of viral disease
JP2015054838A (en) * 2013-09-12 2015-03-23 興和株式会社 Medicament for reduction of blood ldl cholesterol
CN110156779A (en) 2013-11-13 2019-08-23 沃泰克斯药物股份有限公司 Inhibitors of influenza viruses replication
CN108276278A (en) 2013-11-13 2018-07-13 沃泰克斯药物股份有限公司 The method for preparing inhibitors of influenza viruses replication
JP2017521424A (en) 2014-07-07 2017-08-03 ザヴィラ ファーマシューティカルズ ゲーエムベーハー Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
AU2015306458B2 (en) * 2014-08-22 2019-05-02 Cancer Research Technology Ltd. Indazoles
CN104496947A (en) * 2014-12-02 2015-04-08 中国科学院昆明植物研究所 Ganoderma lucidum compounds and medicine composition thereof, as well as preparation method and application of compounds
WO2016128349A1 (en) 2015-02-09 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
JP2018515527A (en) 2015-05-13 2018-06-14 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Inhibitors of influenza virus replication
JP6704416B2 (en) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Methods for preparing inhibitors of influenza virus replication
AU2015406253A1 (en) 2015-08-20 2018-04-05 Changzhou Jiekai Pharmatech Co., Ltd. Pyrazolo fused heterocyclic compounds as ERK inhibitors
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
US20170081323A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease
US20170081324A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20170100396A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
CN109415345A (en) 2016-06-29 2019-03-01 豪夫迈·罗氏有限公司 Broad spectrum influenza inhibitor based on pyridazinone

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030710A1 (en) * 1997-12-13 1999-06-24 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
WO2006083271A2 (en) * 2004-05-18 2006-08-10 Achillion Pharmaceuticals, Inc. Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2006110762A2 (en) * 2005-04-11 2006-10-19 Achillion Pharmaceutical compositions for and methods of inhibiting hcv replication
US20070010455A1 (en) * 2005-07-11 2007-01-11 Piyasena Hewawasam Hepatitis C virus inhibitors
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
WO2008082484A1 (en) * 2006-12-22 2008-07-10 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030710A1 (en) * 1997-12-13 1999-06-24 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
WO2006083271A2 (en) * 2004-05-18 2006-08-10 Achillion Pharmaceuticals, Inc. Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2006110762A2 (en) * 2005-04-11 2006-10-19 Achillion Pharmaceutical compositions for and methods of inhibiting hcv replication
US20070010455A1 (en) * 2005-07-11 2007-01-11 Piyasena Hewawasam Hepatitis C virus inhibitors
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
WO2008082484A1 (en) * 2006-12-22 2008-07-10 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ATTABY, FAWZY ET AL: "Synthesis, Reactions, and Antiviral Activity of 1-(1H-Pyrazolo[3,4-b]pyridin-5-yl)ethanone and Pyrido[2',3':3,4]pyrazolo[5,1-c][1,2,4]triazine Derivatives", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, vol. 181, no. 5, 2010, pages 1087 - 1102, XP008130501 *
DORSEY, BRUCE D. ET AL: "Identification of MK-944a: A Second Clinical Candidate from the Hydroxylaminepentanamide Isostere Series of HIV Protease Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 18, 2000, pages 3386 - 3399, XP002614402 *
LACOVA, MARGITA ET AL: "3-formylchromones IV. The rearrangement of 3-formylchromone enamines as a simple, facile route to novel pyrazolo[3,4-b]pyridines and the synthetic utility of the latter", MOLECULES, vol. 10, no. 7, 2005, pages 809 - 821, XP002614406 *
RYABUKHIN, SERGEY V. ET AL: "Chlorotrimethylsilane-mediated synthesis of functionalized fused pyridines: reaction of 3-formylchromones with electron-rich aminoheterocycles", SYNTHESIS, vol. 12, 2007, pages 1861 - 1871, XP002614405 *
SANGHVI, YOGESH S. ET AL: "Synthesis and biological evaluation of certain C-4 substituted pyrazolo[3,4-b]pyridine nucleosides", JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 5, 1989, pages 945 - 951, XP002614401 *

Also Published As

Publication number Publication date
WO2011000566A2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
AU2020202914A1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CY1117673T1 (en) Recombinant antigens rsv
PH12014501738B1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
CL2015000487A1 (en) Compounds derived sulfamoilarilamidas; pharmaceutical composition comprising the same, useful for the prevention or treatment of an infection by the Hepatitis B Virus (HBV).
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
IL229072D0 (en) 1,3-oxazines as bace1 and/or bace2 inhibitors
EA201590384A1 (en) 6-amino acid-heteroarydyhydropyrimidines for the treatment and prevention of infection of the hepatitis b virus
MX2014014766A (en) Macrocyclic inhibitors of flaviviridae viruses.
MD20150092A2 (en) Amide derivatives for the treatment of HIV infection
PH12017501258A1 (en) Pyrazine compounds for the treatment of infectious diseases
PH12018550201A1 (en) Hepatitis b antiviral agents
GT201400053A (en) Inhibitors of viral application
SI2861601T1 (en) Macrocyclic inhibitors of flaviviridae viruses
PH12013502033B1 (en) Pyrimidine derivatives for the treatment of viral infections
TN2013000421A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
PH12018550148A1 (en) Hepatitis b antiviral agents
CL2013001428A1 (en) Compound that inhibits the activity of the Hepatitis C virus (HCV); pharmaceutical composition comprising the compound; method of treatment of hepatitis c.
CL2013003360A1 (en) "Compounds derived from 4-aryl-N- [3- (sulfonimidoyl) phenyl] -1,3,5-triazin-2-amine substituted cdk inhibitors; intermediate compounds, composition and pharmaceutical combination which comprises; and their use in the treatment of hyperproliferative diseases, infectious virus-induced and / or cardiovascular ". pct
IL228906D0 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
MX2013013692A (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors.
TN2012000369A1 (en) 5-alkynyl-pyrimidines
CO6460769A2 (en) Inhibitors novel viral replication
NZ702458A (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
CL2014000468A1 (en) Compounds derived from the acid 2-oxo-6- (phenyl / heteroaryl) l-1,2-dihydropyridine-3-carboxylic acid; pharmaceutical composition; combination; and its use for the relief of a bacterial infection.
EA201590358A1 (en) Inhibitors of Human Immunodeficiency Virus Replication

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10729816

Country of ref document: EP

Kind code of ref document: A2